Kymera Therapeutics (KYMR) Cash from Financing Activities (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Cash from Financing Activities data on file, last reported at $18.8 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 7174.81% year-over-year to $18.8 million in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 295.23% increase from a year earlier, with the FY2025 full-year figure at $990.7 million, up 62.72% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $18.8 million, down from $705.2 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for KYMR reached as high as $705.2 million in Q4 2025 and fell as low as -$206000.0 in Q3 2023.
• Historically, Cash from Financing Activities has averaged $104.4 million across 5 years, with a median of $2.0 million in 2022.
• Across the five-year window, Cash from Financing Activities tumbled 100.14% in 2023 and surged 121904.85% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $2.0 million in 2022, then declined by 0.97% to $1.9 million in 2023, then surged by 42.97% to $2.8 million in 2024, then surged by 25405.21% to $705.2 million in 2025, then sank by 97.34% to $18.8 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $18.8 million in Q1 2026, $705.2 million in Q4 2025, and $39.5 million in Q3 2025.